Therapeutic-Specific Areas

J&J's Nipocalimab for FNAIT Gets on Fast Track for Approval

March 30, 2024

FDA granted fast track designation to nipocalimab, which J&J is developing for helping alloimmunized pregnant adults treat FNAIT, a rare disease that poses risk to the fetus or newborn.

Mapp Biopharmaceutical Teams Up with ProBioGen and to Develop Antibody Against Marburg Virus Disease

March 16, 2024

Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection

AbbVie Partners with OSE Immunotherapeutics on Novel mAb for Chronic Inflammation

March 06, 2024

Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.

Research into Cold Cancers Heating Up

March 04, 2024

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Bristol Myers Squibb and SystImmune Enter Global ADC Collaboration Worth Potentially up to $8.4 Billion

December 19, 2023

Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.

Roche to Develop Two Novel RNA-targeted Programs from Ionis for CNS Diseases

October 11, 2023

Roche will gain exclusive worldwide rights to develop, manufacture, and commercialize Ionis’ investigational RNA-based therapeutic candidates for Alzheimer's and Huntington's disease.

Harnessing the Power of Oncolytic Viruses

September 03, 2023

Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.

Bristol Myers Squibb and Evotec Extend Neuroscience Pact

July 21, 2023

Under a global license agreement, Bristol Myers Squibb and Evotec will advance the development of neurodegeneration pipeline assets.

Frontrunner in Therapies for Complement-Mediated Diseases

July 02, 2023

A novel complement therapeutic CTx001 offers a novel approach to treating geographic atrophy.

Marketing Authorization Application Accepted for Sugemalimab in Metastatic Non-small Cell Lung Cancer

December 21, 2022

The MAA is supported by data from the pivotal Phase III GEMSTONE-302 trial that evaluated treatment with sugemalimab in combination with chemotherapy in patients with metastatic NSCLC.